J&J submits emergency use listing to WHO for Covid-19 vaccine
FILE PHOTO: A vial and sryinge are seen in front of a displayed Johnson&Johnson logo in this illustration taken January 11, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
Johnson & Johnson (J&J) said Friday it had submitted for emergency use listing of its Covid-19 vaccine to the World Health Organization (WHO).
The company said the process is a prerequisite to supply vaccines to the COVAX vaccine program co-led by WHO, which aims to deliver doses to poor and middle-income countries.
J&J entered into an agreement in December in support of the COVAX program.
The company and Gavi, which also co-leads the COVAX program, expect to enter into an advance purchase agreement that would provide up to 500 million doses of the single-dose vaccine to COVAX through 2022, J&J said.
For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.
The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.
